Trial · NCT06464991
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
NCT06464991, Phase 3, Active not recruiting, Nanjing IASO Biotechnology Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03). Trials, record NCT06464991. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06464991
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- NCT number
- NCT06464991
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 260 participants, estimated
- Lead sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Conditions
- Multiple Myeloma
- Interventions
- Equecabtagene Autoleucel Injection, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone
- First posted
- 2024-06-18
- Last updated
- 2026-11-06
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Minimal Residual Disease (MRD)-negative complete response (CR) rate at 12 months | 12 months (+/-3 months) post-randomization | The proportion of the first 126 randomized subjects who achieved a complete response (CR) or better, as assessed by Independent Review Committee (IRC), and were MRD-negative (assessed by next-generation flow cytometry \[NGF\] using the EuroFlow standard operating procedure) at 12 months (+/-3 months) post-randomization. |
| Primary | Progression-Free Survival (PFS) as assessed by Independent Review Committee (IRC) | up to 5 years from randomization | The time from randomization to the first IRC-assessed disease progression or death from any cause. |
| Secondary | Overall MRD negativity rate | up to 5 years from randomization | The proportion of subjects who achieve MRD negativity at any time after the date of randomization and before the initiation of subsequent therapy |
| Secondary | Duration of MRD negativity | up to 5 years from randomization | The time from first achievement of MRD negativity to the first subsequent positive MRD status |
| Secondary | Complete Response Rate（CRR） | up to 5 years from randomization | The proportion of subjects who achieve CR or better post-randomization among all randomized subjects |
| Secondary | Very good partial response or better response (≥VGPR) rate | up to 5 years from randomization | The proportion of subjects who achieve sCR, CR, or VGPR post-randomization among all randomized subjects |
| Secondary | Overall Response Rate（ORR） | up to 5 years from randomization | The proportion of subjects who achieve sCR, CR, VGPR, or PR post-randomization among all randomized subjects. |
| Secondary | Duration of Response (DOR) | up to 5 years from randomization | The time from the first date of initial documented response (≥PR) to the date of first disease progression or death from any cause, whichever occurs first, post-randomization |
| Secondary | Event-Free Survival (EFS) | up to 5 years from randomization | Time from randomization to the first occurrence of any of the following events: death, disease progression, initiation of a new anti-myeloma therapy, addition of other treatments, or occurrence of fatal or intolerable adverse effects |
| Secondary | Overall Survival（OS） | up to 5 years from randomization | Defined as the time from randomization to death due to any cause |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06464991
GET https://conductscience.org/api/trials/v1/NCT06464991/registered